This section highlights FDA-related milestones and regulatory updates for drugs developed by Agilent Technologies (A).
Over the past two years, Agilent Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
PD-L1 and SK032. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
PD-L1 IHC 22C3 pharmDx FDA Regulatory Events
PD-L1 IHC 22C3 pharmDx is a drug developed by Agilent Technologies for the following indication: Non-small cell lung cancer (NSCLC).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- PD-L1 IHC 22C3 pharmDx
- Announced Date:
- March 26, 2026
- Indication:
- Non-small cell lung cancer (NSCLC)
Announcement
Agilent Technologies Inc announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy.
AI Summary
Agilent Technologies announced U.S. FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA (pembrolizumab). The test detects PD-L1 expression using a Combined Positive Score (CPS) threshold of ≥1.
Clinically, the assay is intended to find tumors that express PD-L1 so doctors can consider KEYTRUDA in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic disease not suitable for surgery or definitive chemoradiation. Using a validated companion diagnostic can help match patients to immunotherapy based on their tumor’s PD-L1 status.
Agilent developed the PD-L1 IHC 22C3 pharmDx in partnership with Merck. The approval arrives as esophageal cancer remains a serious health concern in the U.S., with thousands of deaths annually and a five-year survival under 22%.
Read Announcement- Drug:
- PD-L1 IHC 22C3 pharmDx
- Announced Date:
- February 11, 2026
- Indication:
- Non-small cell lung cancer (NSCLC)
Announcement
Agilent Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy.
AI Summary
Agilent Technologies announced that the U.S. Food and Drug Administration approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA‑approved companion diagnostic indicated to aid in identifying first‑line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) whose tumors express PD‑L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti‑PD‑1 therapy. The test enables pathologists to assess PD‑L1 expression at the time of diagnosis, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients.
PD‑L1 IHC 22C3 pharmDx, Code SK006, was evaluated in the KEYNOTE‑B96 clinical trial to support its use in selecting first‑line patients who may benefit from KEYTRUDA. Developed by Agilent in partnership with Merck, the assay is intended to guide clinicians at diagnosis. In the U.S., ovarian cancer caused about 12,730 deaths in 2025 and has a five‑year survival rate near 51.6%, underscoring the need for better diagnostic and treatment tools.
Read Announcement
SK032 FDA Regulatory Events
SK032 is a drug developed by Agilent Technologies for the following indication: For Use with Newly Approved TCR T-Cell Therapy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- SK032
- Announced Date:
- August 2, 2024
- Indication:
- For Use with Newly Approved TCR T-Cell Therapy
Announcement
Agilent Technologies Inc announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy.
AI Summary
Agilent Technologies Inc. recently received FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032), a diagnostic tool designed to help identify patients with synovial sarcoma who may benefit from TECELRA® treatment. TECELRA®, also known as afamitresgene autoleucel or afami-cel, is a MAGE-A4-directed engineered T-cell receptor therapy developed to target cancers overexpressing the MAGE-A4 antigen.
The MAGE-A4 IHC 1F9 pharmDx assay uses immunohistochemistry to detect MAGE-A4 in formalin-fixed paraffin-embedded synovial sarcoma tissue. A positive result indicates that patients could be eligible for TECELRA® therapy, offering a new approach for individuals with advanced synovial sarcoma. This FDA approval underscores Agilent's role in advancing companion diagnostics that support innovative cancer treatments.
Read Announcement
